The business case for quality by design is drawing scrutiny as the cost of QbD-related process design experiments mounts and regulatory incentives languish. FDA officials encourage industry to concentrate on the business benefits of QbD. CMC pilots raised questions about cost effectiveness. McKinsey consultant argues that the QbD business case is strong but little understood. One key is to utilize resources more, as other industries do. Another is to reduce the cost of drugs by speeding up process development like IBM and auto makers did. If it's quick enough, it can wait until after clinical proof of concept. QbD offers $20 billion to $30 billion of additional profits, mainly by reducing the cost of goods sold, particularly through cycle time reduction, and also by improving the productivity of technology development. But perhaps the most important advance would involve basic research such as NIPTE is planning to do that would establish first principles of pharmaceutical engineering, obviating the need for costly and time-consuming empirical design studies.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
